|Articles|March 1, 2013
- Pharmaceutical Executive-03-01-2013
- Volume 0
- Issue 0
PE, March 2013 Cover Image
S
Advertisement
Cover
Articles in this issue
almost 13 years ago
Less Selling, More Timealmost 13 years ago
Test and Learn: Making Confident Decisions on the Commercial Sidealmost 13 years ago
Specialty Service Programs: Gearing up for Next Generation Technologiesalmost 13 years ago
China and the Emerging Markets Challengealmost 13 years ago
Embedding Market Access in Today's Pharma Business Modelalmost 13 years ago
Who's Really in Charge of European Drug Registration?almost 13 years ago
Brand of the Year: Januviaalmost 13 years ago
Early Engagement with Medical Laboratoriesalmost 13 years ago
Pharma in the News: Pharm Exec's Annual Press Auditalmost 13 years ago
Safeguarding the Value of Patent AssetsNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Relation Therapeutics Forms $1.7 Billion Multi-Program Collaboration with Novartis Advancing Therapeutics for Atopic Diseases
2
Pfizer Enters Exclusive Collaboration and License Agreement with Yao Pharma for Oral Small-Molecule GLP-1 Agonists
3
Eli Lilly’s Jaypirca Achieves Primary Endpoint in Head-to-Head Phase III Study Against Imbruvica Treating CLL/SLL
4
Is FDA Streamlining Regulations in the Biosimilar Space?
5
